- call +1-201-465-4211
- email sales@mrinsights.biz
Chronic thromboembolic pulmonary hypertension is observed to be one of the leading causes of severe pulmonary hypertension. It is a type of clinical condition in which pulmonary vascular resistance increases giving rise to pulmonary hypertension and progressive heart failure. According to World Health Organization (WHO), approximately 0.15% to 0.55% of the patients suffering with acute pulmonary embolism develop chronic thromboembolic pulmonary hypertension. Due to non-specific symptoms observed in chronic thromboembolic pulmonary hypertension its diagnosis is complex. However, some of the prominent symptoms of chronic thromboembolic pulmonary hypertension are chest discomfort, breathlessness and fatigue. Chronic thromboembolic pulmonary hypertension market can be segmented on the basis of types of diagnosis such as transthoracic echocardiogram (TTE), ventilation-perfusion (V/Q) scan, pulmonary angiography, heart catheterization, computed tomography (CT) pulmonary angiography and other pulmonary function tests.
Scope of the Report:
This report studies the Chronic Thromboembolic Pulmonary Hypertension market status and outlook of Global and major regions, from angles of players, countries, product types and end industries; this report analyzes the top players in global market, and splits the Chronic Thromboembolic Pulmonary Hypertension market by product type and applications/end industries.
According to market experts, the diagnosis cases of chronic thromboembolic pulmonary hypertension in regions such as Western Europe and North America was high due to presence of modern technology and rising public awareness about this disease. Regions with rare cases included Asia-Pacific and other geographic regions due to low public awareness and absence of modern diagnostic technologies. North America was observed to be the largest market due to increasing awareness related with chronic thromboembolic pulmonary hypertension and high R&D investments in novel disease diagnostic and treatment technologies.
The global Chronic Thromboembolic Pulmonary Hypertension market is valued at xx million USD in 2017 and is expected to reach xx million USD by the end of 2023, growing at a CAGR of xx% between 2017 and 2023.
The Asia-Pacific will occupy for more market share in following years, especially in China, also fast growing India and Southeast Asia regions.
North America, especially The United States, will still play an important role which cannot be ignored. Any changes from United States might affect the development trend of Chronic Thromboembolic Pulmonary Hypertension.
Europe also play important roles in global market, with market size of xx million USD in 2017 and will be xx million USD in 2023, with a CAGR of xx%.
Market Segment by Companies, this report covers
Bayer
Johnson & Johnson
Nippon Shinyaku
GlaxoSmithKline
Sun Pharmaceutical Industries
Scipharm SaRL
Promedica International
Medical Research Network
Gilead Sciences
Daiichi Sankyo
Market Segment by Regions, regional analysis covers
North America (United States, Canada and Mexico)
Europe (Germany, France, UK, Russia and Italy)
Asia-Pacific (China, Japan, Korea, India and Southeast Asia)
South America (Brazil, Argentina, Colombia)
Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)
Market Segment by Type, covers
Transthoracic Echocardiogram (TTE)
Ventilation-Perfusion (V/Q) Scan
Pulmonary Angiography
Heart Catheterization
Computed Tomography (CT) Pulmonary Angiography
Others
Market Segment by Applications, can be divided into
Hospitals
Ambulatory Surgical Centers
Others
The base year for the study has been considered 2019, historic year 2014 and 2018, the forecast period considered is from 2020 to 2027. The regions analyzed for the market include North America, Europe, South America, Asia Pacific, and Middle East and Africa. These regions are further analyzed at the country-level. The study also includes attractiveness analysis of type, application and regions which are benchmarked based on their market size, growth rate and attractiveness in terms of present and future opportunity for understanding the future growth of the market.
Market is segmented on the basis:
The report offers in-depth analysis of driving factors, opportunities, restraints, and challenges for gaining the key insight of the market. The report emphasizes on all the key trends that play a vital role in the enlargement of the market from 2019 to 2026.
The report provides company profile of the key players operating in the market and a comparative analysis based on their business overviews industry offering, segment market share, regional presence, business strategies, innovations, mergers & acquisitions, recent developments, joint venture, collaborations, partnerships, SWOT analysis, and key financial information.
Table of Contents
1 Chronic Thromboembolic Pulmonary Hypertension Market Overview
1.1 Product Overview and Scope of Chronic Thromboembolic Pulmonary Hypertension
1.2 Classification of Chronic Thromboembolic Pulmonary Hypertension by Types
1.2.1 Global Chronic Thromboembolic Pulmonary Hypertension Revenue Comparison by Types (2017-2023)
1.2.2 Global Chronic Thromboembolic Pulmonary Hypertension Revenue Market Share by Types in 2017
1.2.3 Transthoracic Echocardiogram (TTE)
1.2.4 Ventilation-Perfusion (V/Q) Scan
1.2.5 Pulmonary Angiography
1.2.6 Heart Catheterization
1.2.7 Computed Tomography (CT) Pulmonary Angiography
1.2.8 Others
1.3 Global Chronic Thromboembolic Pulmonary Hypertension Market by Application
1.3.1 Global Chronic Thromboembolic Pulmonary Hypertension Market Size and Market Share Comparison by Applications (2013-2023)
1.3.2 Hospitals
1.3.3 Ambulatory Surgical Centers
1.3.4 Others
1.4 Global Chronic Thromboembolic Pulmonary Hypertension Market by Regions
1.4.1 Global Chronic Thromboembolic Pulmonary Hypertension Market Size (Million USD) Comparison by Regions (2013-2023)
1.4.1 North America (USA, Canada and Mexico) Chronic Thromboembolic Pulmonary Hypertension Status and Prospect (2013-2023)
1.4.2 Europe (Germany, France, UK, Russia and Italy) Chronic Thromboembolic Pulmonary Hypertension Status and Prospect (2013-2023)
1.4.3 Asia-Pacific (China, Japan, Korea, India and Southeast Asia) Chronic Thromboembolic Pulmonary Hypertension Status and Prospect (2013-2023)
1.4.4 South America (Brazil, Argentina, Colombia) Chronic Thromboembolic Pulmonary Hypertension Status and Prospect (2013-2023)
1.4.5 Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa) Chronic Thromboembolic Pulmonary Hypertension Status and Prospect (2013-2023)
1.5 Global Market Size of Chronic Thromboembolic Pulmonary Hypertension (2013-2023)
2 Manufacturers Profiles
2.1 Bayer
2.1.1 Business Overview
2.1.2 Chronic Thromboembolic Pulmonary Hypertension Type and Applications
2.1.2.1 Product A
2.1.2.2 Product B
2.1.3 Bayer Chronic Thromboembolic Pulmonary Hypertension Revenue, Gross Margin and Market Share (2016-2017)
2.2 Johnson & Johnson
2.2.1 Business Overview
2.2.2 Chronic Thromboembolic Pulmonary Hypertension Type and Applications
2.2.2.1 Product A
2.2.2.2 Product B
2.2.3 Johnson & Johnson Chronic Thromboembolic Pulmonary Hypertension Revenue, Gross Margin and Market Share (2016-2017)
2.3 Nippon Shinyaku
2.3.1 Business Overview
2.3.2 Chronic Thromboembolic Pulmonary Hypertension Type and Applications
2.3.2.1 Product A
2.3.2.2 Product B
2.3.3 Nippon Shinyaku Chronic Thromboembolic Pulmonary Hypertension Revenue, Gross Margin and Market Share (2016-2017)
2.4 GlaxoSmithKline
2.4.1 Business Overview
2.4.2 Chronic Thromboembolic Pulmonary Hypertension Type and Applications
2.4.2.1 Product A
2.4.2.2 Product B
2.4.3 GlaxoSmithKline Chronic Thromboembolic Pulmonary Hypertension Revenue, Gross Margin and Market Share (2016-2017)
2.5 Sun Pharmaceutical Industries
2.5.1 Business Overview
2.5.2 Chronic Thromboembolic Pulmonary Hypertension Type and Applications
2.5.2.1 Product A
2.5.2.2 Product B
2.5.3 Sun Pharmaceutical Industries Chronic Thromboembolic Pulmonary Hypertension Revenue, Gross Margin and Market Share (2016-2017)
2.6 Scipharm SaRL
2.6.1 Business Overview
2.6.2 Chronic Thromboembolic Pulmonary Hypertension Type and Applications
2.6.2.1 Product A
2.6.2.2 Product B
2.6.3 Scipharm SaRL Chronic Thromboembolic Pulmonary Hypertension Revenue, Gross Margin and Market Share (2016-2017)
2.7 Promedica International
2.7.1 Business Overview
2.7.2 Chronic Thromboembolic Pulmonary Hypertension Type and Applications
2.7.2.1 Product A
2.7.2.2 Product B
2.7.3 Promedica International Chronic Thromboembolic Pulmonary Hypertension Revenue, Gross Margin and Market Share (2016-2017)
2.8 Medical Research Network
2.8.1 Business Overview
2.8.2 Chronic Thromboembolic Pulmonary Hypertension Type and Applications
2.8.2.1 Product A
2.8.2.2 Product B
2.8.3 Medical Research Network Chronic Thromboembolic Pulmonary Hypertension Revenue, Gross Margin and Market Share (2016-2017)
2.9 Gilead Sciences
2.9.1 Business Overview
2.9.2 Chronic Thromboembolic Pulmonary Hypertension Type and Applications
2.9.2.1 Product A
2.9.2.2 Product B
2.9.3 Gilead Sciences Chronic Thromboembolic Pulmonary Hypertension Revenue, Gross Margin and Market Share (2016-2017)
2.10 Daiichi Sankyo
2.10.1 Business Overview
2.10.2 Chronic Thromboembolic Pulmonary Hypertension Type and Applications
2.10.2.1 Product A
2.10.2.2 Product B
2.10.3 Daiichi Sankyo Chronic Thromboembolic Pulmonary Hypertension Revenue, Gross Margin and Market Share (2016-2017)
3 Global Chronic Thromboembolic Pulmonary Hypertension Market Competition, by Players
3.1 Global Chronic Thromboembolic Pulmonary Hypertension Revenue and Share by Players (2013-2018)
3.2 Market Concentration Rate
3.2.1 Top 5 Chronic Thromboembolic Pulmonary Hypertension Players Market Share
3.2.2 Top 10 Chronic Thromboembolic Pulmonary Hypertension Players Market Share
3.3 Market Competition Trend
4 Global Chronic Thromboembolic Pulmonary Hypertension Market Size by Regions
4.1 Global Chronic Thromboembolic Pulmonary Hypertension Revenue and Market Share by Regions
4.2 North America Chronic Thromboembolic Pulmonary Hypertension Revenue and Growth Rate (2013-2018)
4.3 Europe Chronic Thromboembolic Pulmonary Hypertension Revenue and Growth Rate (2013-2018)
4.4 Asia-Pacific Chronic Thromboembolic Pulmonary Hypertension Revenue and Growth Rate (2013-2018)
4.5 South America Chronic Thromboembolic Pulmonary Hypertension Revenue and Growth Rate (2013-2018)
4.6 Middle East and Africa Chronic Thromboembolic Pulmonary Hypertension Revenue and Growth Rate (2013-2018)
5 North America Chronic Thromboembolic Pulmonary Hypertension Revenue by Countries
5.1 North America Chronic Thromboembolic Pulmonary Hypertension Revenue by Countries (2013-2018)
5.2 USA Chronic Thromboembolic Pulmonary Hypertension Revenue and Growth Rate (2013-2018)
5.3 Canada Chronic Thromboembolic Pulmonary Hypertension Revenue and Growth Rate (2013-2018)
5.4 Mexico Chronic Thromboembolic Pulmonary Hypertension Revenue and Growth Rate (2013-2018)
6 Europe Chronic Thromboembolic Pulmonary Hypertension Revenue by Countries
6.1 Europe Chronic Thromboembolic Pulmonary Hypertension Revenue by Countries (2013-2018)
6.2 Germany Chronic Thromboembolic Pulmonary Hypertension Revenue and Growth Rate (2013-2018)
6.3 UK Chronic Thromboembolic Pulmonary Hypertension Revenue and Growth Rate (2013-2018)
6.4 France Chronic Thromboembolic Pulmonary Hypertension Revenue and Growth Rate (2013-2018)
6.5 Russia Chronic Thromboembolic Pulmonary Hypertension Revenue and Growth Rate (2013-2018)
6.6 Italy Chronic Thromboembolic Pulmonary Hypertension Revenue and Growth Rate (2013-2018)
7 Asia-Pacific Chronic Thromboembolic Pulmonary Hypertension Revenue by Countries
7.1 Asia-Pacific Chronic Thromboembolic Pulmonary Hypertension Revenue by Countries (2013-2018)
7.2 China Chronic Thromboembolic Pulmonary Hypertension Revenue and Growth Rate (2013-2018)
7.3 Japan Chronic Thromboembolic Pulmonary Hypertension Revenue and Growth Rate (2013-2018)
7.4 Korea Chronic Thromboembolic Pulmonary Hypertension Revenue and Growth Rate (2013-2018)
7.5 India Chronic Thromboembolic Pulmonary Hypertension Revenue and Growth Rate (2013-2018)
7.6 Southeast Asia Chronic Thromboembolic Pulmonary Hypertension Revenue and Growth Rate (2013-2018)
8 South America Chronic Thromboembolic Pulmonary Hypertension Revenue by Countries
8.1 South America Chronic Thromboembolic Pulmonary Hypertension Revenue by Countries (2013-2018)
8.2 Brazil Chronic Thromboembolic Pulmonary Hypertension Revenue and Growth Rate (2013-2018)
8.3 Argentina Chronic Thromboembolic Pulmonary Hypertension Revenue and Growth Rate (2013-2018)
8.4 Colombia Chronic Thromboembolic Pulmonary Hypertension Revenue and Growth Rate (2013-2018)
9 Middle East and Africa Revenue Chronic Thromboembolic Pulmonary Hypertension by Countries
9.1 Middle East and Africa Chronic Thromboembolic Pulmonary Hypertension Revenue by Countries (2013-2018)
9.2 Saudi Arabia Chronic Thromboembolic Pulmonary Hypertension Revenue and Growth Rate (2013-2018)
9.3 UAE Chronic Thromboembolic Pulmonary Hypertension Revenue and Growth Rate (2013-2018)
9.4 Egypt Chronic Thromboembolic Pulmonary Hypertension Revenue and Growth Rate (2013-2018)
9.5 Nigeria Chronic Thromboembolic Pulmonary Hypertension Revenue and Growth Rate (2013-2018)
9.6 South Africa Chronic Thromboembolic Pulmonary Hypertension Revenue and Growth Rate (2013-2018)
10 Global Chronic Thromboembolic Pulmonary Hypertension Market Segment by Type
10.1 Global Chronic Thromboembolic Pulmonary Hypertension Revenue and Market Share by Type (2013-2018)
10.2 Global Chronic Thromboembolic Pulmonary Hypertension Market Forecast by Type (2018-2023)
10.3 Transthoracic Echocardiogram (TTE) Revenue Growth Rate (2013-2023)
10.4 Ventilation-Perfusion (V/Q) Scan Revenue Growth Rate (2013-2023)
10.5 Pulmonary Angiography Revenue Growth Rate (2013-2023)
10.6 Heart Catheterization Revenue Growth Rate (2013-2023)
10.7 Computed Tomography (CT) Pulmonary Angiography Revenue Growth Rate (2013-2023)
10.8 Others Revenue Growth Rate (2013-2023)
11 Global Chronic Thromboembolic Pulmonary Hypertension Market Segment by Application
11.1 Global Chronic Thromboembolic Pulmonary Hypertension Revenue Market Share by Application (2013-2018)
11.2 Chronic Thromboembolic Pulmonary Hypertension Market Forecast by Application (2018-2023)
11.3 Hospitals Revenue Growth (2013-2018)
11.4 Ambulatory Surgical Centers Revenue Growth (2013-2018)
11.5 Others Revenue Growth (2013-2018)
12 Global Chronic Thromboembolic Pulmonary Hypertension Market Size Forecast (2018-2023)
12.1 Global Chronic Thromboembolic Pulmonary Hypertension Market Size Forecast (2018-2023)
12.2 Global Chronic Thromboembolic Pulmonary Hypertension Market Forecast by Regions (2018-2023)
12.3 North America Chronic Thromboembolic Pulmonary Hypertension Revenue Market Forecast (2018-2023)
12.4 Europe Chronic Thromboembolic Pulmonary Hypertension Revenue Market Forecast (2018-2023)
12.5 Asia-Pacific Chronic Thromboembolic Pulmonary Hypertension Revenue Market Forecast (2018-2023)
12.6 South America Chronic Thromboembolic Pulmonary Hypertension Revenue Market Forecast (2018-2023)
12.7 Middle East and Africa Chronic Thromboembolic Pulmonary Hypertension Revenue Market Forecast (2018-2023)
13 Research Findings and Conclusion
14 Appendix
14.1 Methodology
14.2 Data Source
List of Tables and Figures
Figure Chronic Thromboembolic Pulmonary Hypertension Picture
Table Product Specifications of Chronic Thromboembolic Pulmonary Hypertension
Table Global Chronic Thromboembol
ProactiveWe manage our resources 24/7 to identify issues and address them before they become problems
Quality & ReliabilityWe are committed to providing reliable and highly accurate data with an excellent quality control system
Global Outreach6 Major regions and 40+ countries level analysis accomplished
Competitive PricingOur pricing strategy is highly competitive in the market, without compensating on the quality and the timeline of project delivery
